biotech's

The Cambridge, Mass., biotech's business has been weighed down by production and regulatory problems in recent years at its main production site in Allston, Mass.

Sanofi to Help Genzyme Resolve Manufacturing Woes Thomas Gryta 2011

All I need to do is look into my 4-year old son Augustus' eyes, and know that we as parents, but more as citizens of the globe, need to stand up and demand governmental protection of organic practices in the face of biotech's relentless bullying.

Maria Rodale: A Visit to My Kitchen: Chris Elam from Meatless Monday Maria Rodale 2011

Glaxo says it has faith in the biotech's technology, and the other Sirtris drugs it is testing.

Glaxo Looks for Gene-Research Payoff on Other Drugs Jeanne Whalen 2011

Actelion's Mr. Clozel in February said that despite the recent drug development setbacks, the biotech's clinical pipeline was "very promising".

Actelion 'Needs to Be Fixed' Goran Mijuk 2011

All I need to do is look into my 4-year old son Augustus' eyes, and know that we as parents, but more as citizens of the globe, need to stand up and demand governmental protection of organic practices in the face of biotech's relentless bullying.

Maria Rodale: A Visit to My Kitchen: Chris Elam from Meatless Monday Maria Rodale 2011

Actelion has come under pressure from Elliott Advisors after a series of drug development setbacks hurt its prospects, adding pressure on the biotech's board and management.

Support for Actelion Management Wanes Goran Mijuk 2011

Mr. Viehbacher Wednesday moved to counter that concern, saying Sanofi supports Genzyme's current turnaround plans and would take time before considering tinkering with the Boston biotech's manufacturing.

Sanofi CEO Bets on Genzyme Mimosa Spencer 2011

Chairman aims to quell lengthy dispute with shareholder at annual meeting and refocus on the biotech's growth.

Defending his Actelion Strategy Goran Mijuk 2011

Frustrated with the standstill, Sanofi took its $69-a-share offer public Sunday to put pressure on the U.S. biotech's board.

Time to Talk at Genzyme 2010

PARIS — French drug giant Sanofi-Aventis Thursday said it will further expand its diabetes business with an exclusive worldwide licensing deal with CureDM Group Holdings LLC for the U. S.-based biotech's experimental treatment Pancreate.

Sanofi Expands Diabetes Efforts Mimosa Spencer 2010